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JPET #98384 INTRODUCTION:
Colorectal cancer is the fourth most common type of cancer in Western countries and the second leading cause of death from cancer in North America (Gill et al., 2004) .
Approximately, 40 to 50 percent of patients who undergo potentially curative surgery finally relapse and die of metastatic disease (Andre et al., 2004) . Interestingly some patients develop thrombotic complications during the course of the disease (Tasi et al., 2004) . There is strong evidence that platelets play an important role in the pathophysiology of metastasis (Nash et al., 2002; Gupta and Massague, 2004; Jurasz et al., 2004) . In fact, cancer cells have the ability to induce platelet aggregation that confers several advantages to the survival of the tumor cells and its successful metastasis (Jurasz et al., 2004) . Moreover, this ability to aggregate platelets correlates with the metastatic potential of tumor cells (Gasic et al., 1968; Radomski et al., 1991) .
There are diverse mechanisms involved in tumor cell induced-platelet aggregation (TCIPA), where platelets can be activated by cancer cells releasing ADP, thromboxane A 2 and matrix metalloproteinase-2 Alonso-Escolano et al., 2004) .
Adenosine diphosphate (ADP) is stored in platelet dense granules and it is a potent proaggregatory agent that can be released during TCIPA induced by fibrosarcoma, breast carcinoma and neuroblastoma cells (Bastida et al., 1986; Jurasz et al., 2001; Alonso-Escolano et al., 2004) . However, the role of ADP in platelet aggregation induced by colon cancer cells is not clear (Scarlett et al., 1987; Grignani and Jamieson, 1988) .
Matrix metalloproteinases (MMPs) comprise an ever-growing family of zinc-and calcium-dependent endopeptidases that are capable of degrading most components of the extracellular matrix (Sternlicht and Werb, 2001) . MMPs participate in tissue remodeling in diverse physiologic situations, including embryogenesis, wound healing and angiogenesis (Sternlicht and Werb, 2001) . Moreover, overexpression of these enzymes is also implicated in the degradation of basement membrane facilitating tumor invasion. In addition, we have previously found that platelet aggregation may be mediated via the release of MMP-2 from platelets (Sawicki et al., 1997) . Interestingly, we have also shown that MMP-2 release from platelets and cancer cells, is involved in platelet aggregation induced by human fibrosarcoma HT-1080, lung carcinoma A549 and breast adenocarcinoma MCF7 cells Alonso-Escolano et al., 2004) . Although, the mechanisms of MMP-mediated stimulation of platelets are not well understood, interactions between MMP-2 and platelet receptors could play an important role (Martinez et al., 2001; Galt et al., 2002) .
GPIIb/IIIa is the major platelet surface transmembrane receptor and it plays an important role in platelet aggregation (Shattil et al., 1998) . In addition, platelets contain a pool of this glycoprotein stored in α -granules (Wagner et al., 1996) . Furthermore, GPIb, the von Willebrand factor-binding subunit of the GPIb/V/IX, mediates mainly platelet adhesion (Andrews and Berndt, 2004) . Finally, P selectin, that is also stored in platelet α -granules, mediates platelet-leukocyte aggregation since it is rapidly translocated to the surface upon platelet activation (Andrews and Berndt, 2004) .
We have now established an in vitro experimental model of TCIPA induced by Caco-2 cells. Using this model, we aimed at studying (a) whether intestinal adenocarcinoma cells were able to induce platelet aggregation, (b) molecular mechanisms responsible for the formation of platelet-human intestinal cancer cell aggregates, (c) the abundance of different platelet receptors during TCIPA, and (d) the regulation of Caco-2 inducedplatelet aggregation and the receptor abundance in the presence of several pharmacologic inhibitors of platelet aggregation. 
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and purified from conditioned medium using anion exchange chromatography, size exclusion chromatography and affinity chromatography.
Cell culture
Caco-2 cells, a human intestinal adenocarcinoma cell line, were obtained from the 
Preparation of human washed platelets
Blood was collected from healthy volunteers who had not taken any drugs known to affect platelet function for at least 14 days prior to the study. Washed platelet suspensions (2.5x10 8 platelets/ml) were prepared from blood as previously described (Radomski and Moncada, 1983) .
Platelet aggregation
The interactions between platelets and tumor cells were measured by light aggregometry (Radomski et al., 1991; Jurasz et al., 2001; Alonso-Escolano et al., 2004) .
This article has not been copyedited and formatted. The final version may differ from this version. 
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Briefly, platelet samples (2.5x10 8 /ml) were placed in a whole blood ionized calcium lumiaggregometer (Chronolog Corp., Havertown, PA, U.S.A.), and incubated for 2 min at 37°C, with stirring at 900 r.p.m., prior to the addition of aggregating agents. For most experiments, collagen at a concentration that resulted in maximal aggregation (5µg/ml) was used as a control agonist. TCIPA was initiated by the addition of tumor cells 
Sample preparation for zymography
Briefly, platelets at a concentration of 2.5x10 8 /ml were placed into lumi-aggregometer and tumor cells were added at different concentrations (1.5x10 3 −10 5 ). The aggregates of platelets and tumor cells were collected after 30 min of incubation in the aggregometer.
The samples were centrifuged at 900 x g at room temperature for 10 min, yielding the pellet and the releasate. The pellets were then homogenized on ice 3 times ( 
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pellet homogenate and the releasate were stored at -20C o until assayed for the presence of MMP activity by zymography.
Zymography
Gelatin zymography was used to detect the activity of MMP-2 and MMP-9. Zymographic analysis was carried out on aggregates of platelets and tumor cells, as previously described Alonso-Escolano et al., 2004) . Briefly, samples were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with copolymerized gelatin (0.2%; Sigma Chemical Co, St. Louis, Mo) incorporated as a substrate for gelatinolytic proteases. After electrophoresis, the gels were washed with 2.5% Triton X-100 (3 times, 20 minutes each), and then incubated for 48 h at 37C o in enzyme assay buffer (25 mM Tris HCl, 0.9% NaCl, 5 mM CaCl 2 and JPET #98384
Microscopy of TCIPA
The structure of platelet−tumor cell aggregates was studied using phase-contrast microscopy Alonso-Escolano et al., 2004) . Briefly, Caco-2 cells (1.5x10 3 cells/ml) were added to the platelet suspension (2.5x10 8 /ml) in the presence or absence of TCIPA inhibitors phenantroline and APT102, and aggregation was terminated at 50% maximal aggregation, as determined using the aggregometer. The samples were fixed by adding 2% paraformaldehyde in Tyrode's solution, pH 7.4, and then incubated for 30 min at room temperature. Aliquots of each sample were then taken for phase-contrast microscopy examination using an Olympus CKX41 microscope (Olympus America Inc., Melville, NY, U.S.A.). Photomicrographs were captured using a digital camera and MicroFire (Olympus America Inc.) software Alonso-Escolano et al., 2004) .
Flow cytometry
The abundance of GPIIb/IIIa, GPIb and P selectin on the surface of platelets during TCIPA was measured by flow cytometry Radomski et al., 2001; Chung et al., 2002; Alonso-Escolano et al., 2004) . Platelets were activated with tumor cells (1.5x10
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or P-selectin (CD62P-APC). The activated GPIIb/IIIa platelet receptors were measured using PAC-1 monoclonal antibody at the same concentration as above. PAC-1 specifically recognizes an epitope on the high-affinity GPIIb/IIIa complex of activated platelets at or near the platelet (Abrams et al., 1990) . Following incubation, samples were diluted in FACS Flow fluid and analyzed within 5 min using a Beckman Coulter FC500 dual laser five color flow cytometer. Flow cytometry was performed on single stained platelet samples as described before (Radomski et al., 2005) . 
Statistics
The data were analyzed using one-way analysis of variance (GraphPad Prism software).
The results are expressed as mean ± s.e.m. of at least three independent experiments. Caco-2 cell-Induced Platelet Aggregation
Caco-2 cells were tested for their ability to induce platelet aggregation. When platelets were incubated in the aggregometer for 30 min at 37°C without the addition of tumor cells, no platelet aggregation was detected. However, colon adenocarcinoma cells induced platelet aggregation in a concentration-dependent manner ( Figure 1A and B). In addition, this aggregation was preceded by a lag-phase of several minutes that decreased as the concentration of Caco-2 cells increased ( Figure 1A ). Since the concentration of 1.5x10 3 cells/ml was sufficient to induce platelet aggregation, all remaining experiments were performed with this amount of cells.
MMP-2 Activity in Cancer Cell-Platelet Homogenates and their Releasates.
Zymography was conducted to study whether MMP-2 and MMP-9 were involved in Caco-2-induced platelet aggregation. The pro-MMP-2 was the major gelatinase detected, as shown by the 72 kDa band. Zymography showed a significant decrease in the MMP-2 activity in cancer cell-platelet pellets compared with unaggregated platelets (P < 0.0005; n = 4) when Caco-2 were added to induce platelet aggregation (from 1.5x10 3 to 10 5 cells/ml) (Figure 2A ). In addition, there was a significant increase in MMP-2 activity in the releasate of aggregated platelets induced by Caco-2 in comparison with unaggregated platelets (P<0.0001; n = 4), indicating the enzyme release during TCIPA ( Figure 2B ). No significant differences were found in MMP-9 activity when Caco-2 cells were added to induce platelet aggregation (data no shown).
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Inhibition of Caco-2-Induced Platelet Aggregation
We used selective inhibitors of three TXA 2 , MMPs and ADP (Sawicki et al 1997 to characterize the mechanism of Caco-2-induced platelet aggregation.
Aspirin ( 
Measurement of Platelet Receptors during Caco-2-Induced Aggregation.
The interactions of platelets with tumor cells induced a significant (P<0.005; n=4) increase in the number of copies of activated GPIIb/IIIa (PAC-1) on platelets ( Figure 5A ).
Furthermore, platelet activation with Caco-2 cells (1.5x10 3 cells/ml) resulted in a significant increase in the number of copies of total GPIIb/IIIa (P<0.005; n=4), GPIb (P<0.01; n=4) and P-selectin (P<0.005; n=4) on platelets in comparison with resting platelets ( Figure 5B-D) .
This article has not been copyedited and formatted. The final version may differ from this version. Platelets have been implicated in tumor metastasis and thrombotic complications of patients with colorectal adenocarcinoma (McCarty et al., 2002; Im et al., 2004) .
However, the relative contribution of ADP, MMP-2 and TXA 2 to colon cancer-induced platelet aggregation remains still unclear. Therefore, the aim of our investigation was to study the interactions between human intestinal cancer cells and platelets. Furthermore, we studied the expression of major receptors on the platelet surface during TCIPA. In addition, we tested the effects of different pharmacologic compounds on Caco-2-induced platelet aggregation.
First, we used human colon adenocarcinoma cells, Caco-2, to study their interactions with platelets in vitro. We showed that Caco-2 cells were able to induce platelet aggregation in a concentration-dependent manner, as evidenced by aggregometry.
Knowing that Caco-2 cells stimulated platelet aggregation, we next studied the molecular mechanisms implicated in this interaction. We have previously shown the requirement for activated MMP-2 to induce the MMP-2 dependent pathway both in agonist and TCIPA induced by HT-1080 and MCF7 breast cancer cells AlonsoEscolano et al., 2004) . In the present study, we have found that MMP-2 is released during platelet aggregation induced by Caco-2 cells. We have previously found that MMP-9 may inhibit platelet aggregation counteracting the effects of MMP-2 (FernandezPatron et al., 1999) . However, Caco-2-induced platelet aggregation did not result in significant release of MMP-9 suggesting that MMP-2 is the dominant gelatinase released during Caco-2-induced platelet aggregation. However, we did not study other MMPs such as MMP-1 that has been also involved in agonist platelet aggregation (Galt et al., This article has not been copyedited and formatted. The final version may differ from this version. 
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2002). Therefore, the precise role of this enzyme during TCIPA remains to be elucidated. MMP-2 has been previously involved in colorectal cancer in humans, since this enzyme has been found in regions of tumor invasion (Papadopoulou et al., 2001; Ornstein and Cohn, 2002) . In addition, a single nucleotide polymorphism in the MMP-2 promoter region that increases gene transcriptional activity has been associated with colon cancer development and invasion (Xu et al., 2004) .
Numerous studies have suggested that aspirin and other non-steroidal anti-inflammatory drugs, particularly highly selective COX-2 inhibitors, could be used as chemoprophylactic agents preventing colorectal adenoma and cancer, especially in patients with familiar adenomatous polyposis (Thun et al., 2002) . However, aspirin did not reduce TCIPA in our study, suggesting that TXA2-mediated pathway of aggregation is unlikely to be implicated in Caco-2-induced platelet aggregation.
The role of ADP in colon cancer-induced platelet aggregation is controversial. Some studies have shown that TCIPA induced by colon cell lines is ADP-dependent, since TCIPA was partly abolished by potato apyrase (Scarlett et al., 1987) . However, other researchers have found that colon carcinomas do not promote platelet aggregation through the production of ADP (Grignani and Jamieson, 1988) . Interestingly, during the course of our investigation, human apyrase APT102 was able to attenuate platelet aggregation induced by Caco-2 cells in a concentration-dependent manner. In humans, apyrases maintain vascular fluidity and modulate inflammation by metabolically deleting extracellular ADP and ATP, released by activated platelets (Marcus et al., 2003) .
APT102 is a human apyrase optimized by protein engineering. This protein exhibited a 4-fold higher ADPase activity than the wild-type enzyme CD39L3 and a wellcharacterized isozyme CD39. The improved enzymatic activity was correlated with
significantly higher potency to inhibit and even reverse ADP-induced platelet aggregation (Jeong et al., 2004) . Therefore, taking together, MMP-2 and ADP released during the TCIPA seem to be the major pathways of platelet aggregation triggered by Caco-2.
Since platelet receptors mediate platelet adhesion and aggregation, we next studied the changes in the abundance of these receptors on platelets induced by human colon adenocarcinoma cells. In our study, we found that Caco-2 cells increased the number of copies of GPIIb/IIIa (both non-activated and activated receptors), GPIb and P-selectin, as measured by flow cytometry. GPIIb/IIIa is constitutively expressed as inactive receptor on the platelet surface, but upon platelet aggregation, this receptor becomes active and binds several protein ligands (Bennett, 2001) . GPIb is also constitutively expressed in platelets and its main role is to attach platelets to the injured part of the vascular wall (Ruggeri, 1999) . Both GPIIb/IIIa and GPIb have been implicated in tumor cell-platelet interactions and subsequent tumor metastasis, since colon carcinoma cells pretreated with antibodies against platelet GPIb and/or GPIIb/IIIa inhibited their ability to induce platelet aggregation (Grossi et al., 1988) . P-selectin is mainly stored in platelet α -granules and upon platelet activation, this receptor is translocated to the platelet surface mediating leukocyte rolling and the formation of platelet-leukocyte aggregates (Andrews and Berndt, 2004) . In addition, platelet P-selectin has been involved in colon carcinoma cell tethering and rolling in an in vitro model (McCarty et al., 2000) . Furthermore, it has been previously shown that inhibition of P-selectin-mediated cell adhesion of human colon carcinoma by heparin treatment may have a potential therapeutic value (Wei et al., 2004) .
Since platelet MMP-2 is translocated to platelet surface membrane during aggregation (Sawicki et al., 1998) , we next studied the interaction of this enzyme with the different platelet receptors during TCIPA. We have previously shown that the release of platelet MMP-2 is associated with the activation of GPIIb/IIIa receptor (Martinez et al., 2001) and, furthermore, human recombinant MMP-2 increased GPIb in platelets adhering to von Willebrand factor . Our data showed that the broad-spectrum MMP inhibitor, phenantroline, reduced Caco-2-induced up-regulation of platelet receptors. Therefore, our study suggests that MMP-2 is crucial for the formation of Caco-2-platelet aggregates via activation of the different receptors on the platelet surface.
Interestingly, APT102 also significantly reduced the number of copies of GPIIb/IIIa (both non-activated and activated receptors), GPIb and P selectin on the platelet surface during TCIPA to a similar extent, suggesting that the release of ADP during TCIPA also plays an important role in up-regulation of platelet receptors.
In conclusion, our results show that Caco-2 cells stimulate platelet aggregation through the release of MMP-2 and ADP. The proaggregatory effects of Caco-2 are associated with an increase of platelet GPIb, GPIIb/IIIa and P-selectin receptors. Modulation of MMP-2 and ADP-mediated pathways may represent effective therapeutic approach to prevent or reduce tumor metastasis induced by colon adenocarcinoma.
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